Top

Clinical Neuroradiology

Published in:

01-12-2017 | Original Article

Brain relaxometry after macrocyclic Gd-based contrast agent

Authors: Andreas Müller, Alina Jurcoane, Burkhard Mädler, Philip Ditter, Hans Schild, Elke Hattingen

Published in: Clinical Neuroradiology | Issue 4/2017

Abstract

Purpose

To assess if ratios of T1-weighted (T1w) signal intensity (SI) and quantitative T1 relaxometry (qT1) change on serial administration of macrocyclic gadobutrol.

Methods

A total of 17 glioblastoma patients were scanned at 3.0 T magnetic resonance imaging (MRI) every 6 weeks after tumor resection with standard MRI and T1 and T2 relaxometry before and after gadobutrol administration. On co-registered images T1w SI was measured and relaxation times T1 (qT1) and quantitative T2 (qT2) were quantified in several deep grey matter nuclei as ratios relative to frontal white matter and to the pons. Ratio changes were evaluated over time with a paired t‑test and multiple regression.

Results

An average of 8 (range 5–14) scans per patient were completed. Ratios of T1w SI, qT1 and qT2 remained unchanged for all target regions from the first to the last time point (p > 0.05) and did not correlate with the number of gadobutrol administrations. Multivariate regression showed no significant impact of gadobutrol on qT1 or qT2 ratios, but a significant negative effect on T1w SI ratios. Gender also had no impact on the ratios but age had a significant negative influence on the qT1 ratio.

Conclusion

Multiple administrations of a macrocyclic contrast agent did not change relaxation time T1 ratios in any deep grey matter structure.

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834–41.CrossRefPubMed

Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol. 2016;37:1192–8.CrossRefPubMed

Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012;5:82–8.CrossRefPubMedPubMedCentral

Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients. Scand J Urol Nephrol. 2007;41:565–6.CrossRefPubMed

Roccatagliata L, Vuolo L, Bonzano L, Pichiecchio A, Mancardi GL. Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. Radiology. 2009;251:503–10.CrossRefPubMed

Radbruch A, Weberling LD, Kieslich PJ, Eidel O, Burth S, Kickingereder P, Heiland S, Wick W, Schlemmer H‑P, Bendszus M. Gadolinium retention in the dentate nucleus and Globus Pallidus is dependent on the class of contrast agent. Radiology. 2015;275:150337.CrossRef

Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M. High-signal intensity in the dentate nucleus and Globus Pallidus on Unenhanced T1-weighted images: evaluation of the Macrocyclic gadolinium-based contrast agent Gadobutrol. Invest Radiol. 2015;50:805–10.CrossRefPubMed

Radbruch A, Haase R, Kickingereder P, Bäumer P, Bickelhaupt S, Paech D, Wick W, Schlemmer HP, Seitz A, Bendszus M. Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a Macrocyclic gadolinium-based contrast agent. Radiology. 2017;283:828–36.CrossRefPubMed

Radbruch A, Haase R, Kieslich PJ, Weberling LD, Kickingereder P, Wick W, Schlemmer HP, Bendszus M. No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of Macrocyclic gadolinium-based contrast agents. Radiology. 2017;282:699–707.CrossRefPubMed

10.

Chandra T, Mohan S. Role of contrast in MR imaging. Top Magn Reson Imaging. 2016;25:151–156.

11.

Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol. 2003;13:2688–98.CrossRefPubMed

12.

Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293–352.CrossRefPubMed

13.

Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast age. Eur Radiol. 2016;26:807–15.CrossRefPubMed

14.

Tedeschi E, Palma G, Canna A, Cocozza S, Russo C, Borrelli P, Lanzillo R, Angelini V, Postiglione E, Morra VB, Salvatore M, Brunetti A, Quarantelli M. In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents. Eur Radiol. 2016;26:4577–84.CrossRef

15.

Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276:228–32.CrossRefPubMed

16.

Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and Bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol. 2016;51:447–53.CrossRefPubMed

17.

McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772–82.

18.

Nyúl LG, Udupa JK. On standardizing the MR image intensity scale. Magn Reson Med. 1999;42:1072–81.CrossRefPubMed

19.

Deoni SCL. Quantitative relaxometry of the brain. Top Magn Reson Imaging. 2010;21:101–13.CrossRefPubMedPubMedCentral

20.

Weiskopf N, Suckling J, Williams G, Correia MMM, Inkster B, Tait R, Ooi C, Bullmore TET, Lutti A. Quantitative multi-parameter mapping of R1, PD*, MT, and R2* at 3T: A multi-center validation. Front Neurosci. 2013;7:1–11.CrossRef

21.

Müller A, Jurcoane A, Kebir S, Ditter P, Schrader F, Herrlinger U, Tzaridis T, Mädler B, Schild HH, Glas M, Hattingen E. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma. Cancer Med. 2017;6(1):89–99. doi:10.1002/cam4.966.CrossRefPubMed

22.

Mädler B, Harris T, MacKay AL. 3D-relaxometry—quantitative T1 and T2 brain mapping at 3T. Proceedings of the 14th scientific meeting, International Society for Magnetic Resonance in Medicine, Seattle, USA, 2006, 14, p. 958.

23.

Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011;46:292–300.CrossRefPubMed

24.

Jost G, Frenzel T, Lohrke J, Lenhard DC, Naganawa S, Pietsch H. Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol. 2016;27:2877–85.CrossRefPubMedPubMedCentral

25.

Frenzel T, Apte C, Jost G, Schöckel L, Lohrke J, Pietsch H. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Invest Radiol. 2017;52(7):396–404. doi:10.1097/RLI.0000000000000352.

26.

Badve C, Yu A, Rogers M, Ma D, Liu Y, Schluchter M, Sunshine J, Griswold M, Gulani V. Simultaneous T1 and T2 brain relaxometry in asymptomatic volunteers using magnetic resonance fingerprinting. Tomography. 2015;1:136–44.CrossRefPubMedPubMedCentral

27.

Gracien RM, Nürnberger L, Hok P, Hof SM, Reitz SC, Rüb U, Steinmetz H, Hilker-Roggendorf R, Klein JC, Deichmann R, Baudrexel S. Evaluation of brain ageing: a quantitative longitudinal MRI study over 7 years. Eur Radiol. 2016;27:1568–76.CrossRefPubMed

Title: Brain relaxometry after macrocyclic Gd-based contrast agent
Authors: Andreas Müller
Alina Jurcoane
Burkhard Mädler
Philip Ditter
Hans Schild
Elke Hattingen
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Clinical Neuroradiology / Issue 4/2017
Print ISSN: 1869-1439
Electronic ISSN: 1869-1447
DOI: https://doi.org/10.1007/s00062-017-0608-6

At a glance: The STEP trials

Springer Medicine

Brain relaxometry after macrocyclic Gd-based contrast agent

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2017

Optimization of the Surgical Approach in AVMs Using MRI and 4D DSA Fusion Technique

Magnetic Resonance Imaging and Clinical Features in Acute and Subacute Myelopathies

Information

Carotid Stenting in Neuroradiology

Time-resolved 3D Rotational Angiography (4D DSA) of the Lenticulostriate Arteries: Display of Normal Anatomic Variants and Collaterals in Cases with Chronic Obstruction of the MCA

IVIM perfusion fraction is prognostic for survival in brain glioma